Literature DB >> 9191958

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.

G W Rewcastle1, A J Bridges, D W Fry, J R Rubin, W A Denny.   

Abstract

A series of 6-substituted 4-anilinopyrimido[5,4-d]pyrimidines has been prepared and shown to be potent inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). These compounds are structurally related to the pyrido[3,2-d]- and pyrido[3,4-d]-pyrimidines previously shown to be EGFR inhibitors. Their structure-activity relationships (SAR) for inhibition of the isolated enzyme more closely resemble those of the [3,2-d] than the [3,4-d] pyridopyrimidine isomers. This suggests the requirement of an aza atom in the 7- but not the 5-position (i.e., a carbon atom in the 5-position) for the enhanced potency shown by 6-N-methylated derivatives in each series. X-ray crystal structures were determined for the three NHMe derivatives 2, 3, and 5c in the pyrido[9,2-d]-, pyrido[3,4-d]-, and pyrimido[5,4-d]-pyrimidine series, respectively. These show that a carbon rather than a nitrogen atom at the 5-position leads to significant conformational changes in the molecule (a longer C5a-C4 bond and a 30 degrees out-of-plane rotation of the phenyl group), due to the requirement to relieve nonbonding interactions between the C5 and N9 protons. Pyrimido[5,4-d]pyrimidine analogues bearing bulky, weakly basic solubilizing side chains linked to the 6-position through a secondary amine generally retained potency both against the isolated enzyme and for inhibition of autophosphorylation of EGFR in intact A431 cells. This agrees with a recent binding model that suggests this general class of compounds binds to EGFR with the 6-position located in an area of comparative bulk tolerance at the entrance to the ATP-binding pocket. While these solubilized pyrimido[5,4-d]pyrimidine analogues were less potent than the NHMe derivative 5c in the isolated enzyme assay, some were considerably superior to 5c (and among the most potent ever reported) as inhibitors of EGFR autophosphorylation in cellular assays.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9191958     DOI: 10.1021/jm960879m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents.

Authors:  Samir M El-Moghazy; Diaa A Ibrahim; Nagwa M Abdelgawad; Nahla A H Farag; Ahmad S El-Khouly
Journal:  Sci Pharm       Date:  2011-05-08

2.  Synthesis, X-ray and Fluorescence Characteristics of Pyrimido[5,4-e]thiazolo[3,2-a]pyrimidine as a Novel Heterocyclic System.

Authors:  Zahra Ebrahimpour; Mehdi Bakavoli; Ali Shiri; Seyed Mohammad Seyedi; Tayebe Asghari; Joel T Mague
Journal:  J Fluoresc       Date:  2017-03-10       Impact factor: 2.217

Review 3.  A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.

Authors:  Tanuja T Yadav; Gulam Moin Shaikh; Maushmi S Kumar; Meena Chintamaneni; Mayur Yc
Journal:  Front Chem       Date:  2022-06-13       Impact factor: 5.545

4.  An efficient and environmentally sustainable domino protocol for the synthesis of structurally diverse spiroannulated pyrimidophenazines using erbium doped TiO2 nanoparticles as a recyclable and reusable heterogeneous acid catalyst.

Authors:  Kanchan Verma; Yogesh Kumar Tailor; Sarita Khandelwal; Monu Agarwal; Esha Rushell; Yogita Kumari; Kamlendra Awasthi; Mahendra Kumar
Journal:  RSC Adv       Date:  2018-08-28       Impact factor: 4.036

5.  Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.

Authors:  Hongying Du; Zhide Hu; Andrea Bazzoli; Yang Zhang
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

6.  2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors.

Authors:  Manman Zhao; Lin Wang; Linfeng Zheng; Mengying Zhang; Chun Qiu; Yuhui Zhang; Dongshu Du; Bing Niu
Journal:  Biomed Res Int       Date:  2017-05-29       Impact factor: 3.411

Review 7.  Bicyclic 6 + 6 systems: the chemistry of pyrimido[4,5-d]pyrimidines and pyrimido[5,4-d]pyrimidines.

Authors:  M Monier; Doaa Abdel-Latif; Ahmed El-Mekabaty; Khaled M Elattar
Journal:  RSC Adv       Date:  2019-09-30       Impact factor: 4.036

Review 8.  Advances in the chemical and biological diversity of heterocyclic systems incorporating pyrimido[1,6-a]pyrimidine and pyrimido[1,6-c]pyrimidine scaffolds.

Authors:  Khaled M Elattar; Başak Doğru Mert; M Monier; Ahmed El-Mekabaty
Journal:  RSC Adv       Date:  2020-04-20       Impact factor: 4.036

9.  A Computational QSAR, Molecular Docking and In Vitro Cytotoxicity Study of Novel Thiouracil-Based Drugs with Anticancer Activity against Human-DNA Topoisomerase II.

Authors:  Doaa M Khaled; Mohamed E Elshakre; Mahmoud A Noamaan; Haider Butt; Marwa M Abdel Fattah; Dalia A Gaber
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

10.  Facile construction of substituted pyrimido[4,5-d]pyrimidones by transformation of enaminouracil.

Authors:  Wafaa S Hamama; Mohamed A Ismail; Hanaa A Al-Saman; Hanafi H Zoorob
Journal:  J Adv Res       Date:  2012-05-16       Impact factor: 10.479

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.